Krzysztof Misiukiewicz

Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center

Papers

7

Total Citations

198

H-Index

6

About

Krzysztof Misiukiewicz is a physician-scientist at the forefront of precision oncology and head and neck cancer research. His work bridges innovative drug discovery platforms and personalized medicine, most notably through the development of a *Drosophila*‑based screening system. In a landmark 2019 study (107 citations), this platform identified the combination of trametinib and zoledronate for a patient with KRAS‑mutant metastatic colorectal cancer, leading to a dramatic 11‑month partial response. He further demonstrated the power of this approach in adenoid cystic carcinoma (38 citations), offering new hope for rare, treatment‑refractory tumors. In head and neck oncology, Misiukiewicz has redefined surgical and radiation strategies for HPV‑related oropharyngeal cancer, including seminal work on contralateral nodal disease risk (14 citations) and the optimization of transoral robotic surgery (TORS) with adjuvant therapy (14 citations). His long‑term outcome studies (10 citations) and window‑of‑opportunity trials of *Listeria*‑based immunotherapy (2 citations) underscore his commitment to translating bench discoveries into tangible patient benefit. With over 200 cumulative citations, Misiukiewicz’s research is shaping the future of personalized cancer therapy and surgical oncology.

Research Focus

Key Achievements

6
H-Index
7
Papers
198
Total Citations
28
Avg Citations/Paper
🏆 Most Cited Paper
A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer
107 citations · 2019
📈 Most Prolific Year: 2019 (2 Papers)
🤝 Key Collaborators: 59
🏛 Institutions: Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 15 days ago